These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 11365859)

  • 1. OI prophylaxis in antiretroviral responders: stay the course or bite the bullet?
    Currier JS
    AIDS Clin Care; 1998 Oct; 10(10):73-5, 79-80. PubMed ID: 11365859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opportunistic infections: stemming the tide.
    MacDougall DS
    J Int Assoc Physicians AIDS Care; 1997 Apr; 3(4):42-7. PubMed ID: 11364202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
    Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
    Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility to opportunistic infections in HIV-infected patients with increased CD4 T-cell counts on antiretroviral therapy may be predicted by markers of dysfunctional effector memory CD4 T cells and B cells.
    French M; Keane N; McKinnon E; Phung S; Price P
    HIV Med; 2007 Apr; 8(3):148-55. PubMed ID: 17461858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on opportunistic infections.
    Proj Inf Perspect; 1997 Nov; (23):16-7. PubMed ID: 11365373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune reconstitution in several forms.
    Ball SC
    AIDS Read; 2005 Jan; 15(1):17-20. PubMed ID: 15685730
    [No Abstract]   [Full Text] [Related]  

  • 7. Does Pneumocystis carinii prophylaxis still need to be lifelong?
    Masur H; Kaplan J
    N Engl J Med; 1999 Apr; 340(17):1356-8. PubMed ID: 10219072
    [No Abstract]   [Full Text] [Related]  

  • 8. Discontinuation of Mycobacterium avium complex prophylaxis in patients with a rise in CD4 cell count following highly active antiretroviral therapy.
    Gill J; Moyle G; Nelson M
    AIDS; 1998 Apr; 12(6):680. PubMed ID: 9583614
    [No Abstract]   [Full Text] [Related]  

  • 9. Stopping preventive treatments.
    Fornataro K; Jefferys R
    Body Posit; 1999 Jul; 12(7):9-10. PubMed ID: 11367080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.
    Jones JL; Hanson DL; Dworkin MS; Alderton DL; Fleming PL; Kaplan JE; Ward J
    MMWR CDC Surveill Summ; 1999 Apr; 48(2):1-22. PubMed ID: 12412613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrence of Mycobacterium avium infection in patients receiving highly active antiretroviral therapy and antimycobacterial agents.
    Cinti SK; Kaul DR; Sax PE; Crane LR; Kazanjian PH
    Clin Infect Dis; 2000 Mar; 30(3):511-4. PubMed ID: 10722436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective multicentre study of discontinuing prophylaxis for opportunistic infections after effective antiretroviral therapy.
    Green H; Hay P; Dunn DT; McCormack S;
    HIV Med; 2004 Jul; 5(4):278-83. PubMed ID: 15236617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy.
    Jacobson MA; French M
    AIDS; 1998; 12 Suppl A():S157-63. PubMed ID: 9632998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical impact of combination antiretroviral therapy].
    Gatanaga H
    Nihon Rinsho; 2002 Apr; 60(4):739-44. PubMed ID: 11968781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination.
    López-Palomo C; Martín-Zamorano M; Benítez E; Fernández-Gutiérrez C; Guerrero F; Rodríguez-Iglesias M; Girón-González JA
    J Med Virol; 2004 Apr; 72(4):517-24. PubMed ID: 14981752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
    Mussini C; Pezzotti P; Govoni A; Borghi V; Antinori A; d'Arminio Monforte A; De Luca A; Mongiardo N; Cerri MC; Chiodo F; Concia E; Bonazzi L; Moroni M; Ortona L; Esposito R; Cossarizza A; De Rienzo B
    J Infect Dis; 2000 May; 181(5):1635-42. PubMed ID: 10823763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. I hear you knockin' (but you can't come in): potent new HIV therapies are shutting out opportunistic infections.
    Fichtenbaum CJ
    Res Initiat Treat Action; 1998 Jul; 4(4):3-7. PubMed ID: 11365645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Joint effects of HIV-1 RNA levels and CD4 lymphocyte cells on the risk of specific opportunistic infections.
    Williams PL; Currier JS; Swindells S
    AIDS; 1999 Jun; 13(9):1035-44. PubMed ID: 10397533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preaching what we practice: new guidelines for OI prophylaxis.
    Feinberg J
    AIDS Clin Care; 1999 Nov; 11(11):87-9, 94. PubMed ID: 11366709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of primary prophylaxis against Mycobacterium avium complex infection in HIV-infected persons receiving antiretroviral therapy: observations from a large national cohort in the United States, 1992-2002.
    Brooks JT; Song R; Hanson DL; Wolfe M; Swerdlow DL;
    Clin Infect Dis; 2005 Aug; 41(4):549-53. PubMed ID: 16028167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.